---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-034910"
form_type: "8-K"
ticker: "GOVX"
cik: "0000832489"
company_name: "GeoVax Labs, Inc."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T01:25:26.593597+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# GeoVax Q3 net loss $5.8M ($0.91/share); BARDA NextGen trial on track; special meeting adjourned

## Summary
- Net loss $5.8M for Q3 2024 ($0.91/share) vs $8.4M ($4.75/share) in Q3 2023; nine-month net loss $16.7M ($4.52/share).
- Revenue of $2.8M from BARDA/RRPV Project NextGen award (no revenue in prior year period).
- Cash $8.6M at Sep 30, 2024, vs $6.5M at Dec 31, 2023.
- BARDA Phase 2b trial of GEO-CM04S1 (10,000 patients) preparing for activation; sites confirmed.
- Special Meeting adjourned without business due to lack of quorum (30.4% proxy turnout); reconvened Dec 18, 2024.

## SEC filing metadata
- accession: 0001437749-24-034910
- form_type: 8-K
- ticker: GOVX
- cik: 0000832489
- company_name: GeoVax Labs, Inc.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/832489/000143774924034910/0001437749-24-034910-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/832489/000143774924034910/govx20241113_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-034910
- JSON: https://secwatch.observer/filing/0001437749-24-034910.json
- Plain text: https://secwatch.observer/filing/0001437749-24-034910.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.